A leading biotechnology company focused on developing and manufacturing biologic therapies for oncology, cardiovascular disease, inflammation, and rare disorders. Its portfolio includes blockbuster drugs such as Enbrel, Prolia, and Otezla, alongside a growing pipeline of biosimilars and novel biologics. Investors closely monitor product sales concentration, patent expirations, clinical trial outcomes, and capital allocation as key drivers of revenue growth and margin stability.
9 members of Congress have disclosed 20 trades in Amgen Inc. (AMGN), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 13 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2007-09-10 | Vern Buchanan | buy | $1K – $15K |
| 2007-06-11 | JANE HARMAN | buy | $50K – $100K |
| 2007-02-07 | MICHAEL T. MCCAUL | buy | (22,654.94) |
| 2007-01-03 | MICHAEL T. MCCAUL | sell | $49,809.24 |
| 2007-01-03 | MICHAEL T. MCCAUL | sell | $49,809.24 |
| 2006-11-08 | Ed Whitfield | sell | $1K – $15K |
| 2006-01-22 | Alan Grayson | sell | $50K – $100K |
| 2004-03-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2004-02-07 | Niki Tsongas | sell | $1K – $15K |
| 2003-12-07 | MARY BONO MACK | sell | $1K – $15K |
| 2003-12-07 | MARY BONO MACK | sell | $1K – $15K |
| 2003-12-07 | MARY BONO MACK | sell | $1K – $15K |
| 2003-12-07 | CONNIE MACK | sell | $1K – $15K |
| 2003-12-07 | MARY BONO MACK | sell | $1K – $15K |
| 2003-12-07 | CONNIE MACK | sell | $1K – $15K |
| 2003-12-07 | CONNIE MACK | sell | $1K – $15K |
| 2003-12-07 | CONNIE MACK | sell | $1K – $15K |
| 2003-12-07 | MARY BONO MACK | buy | $1K – $15K |
| 2002-11-10 | Lamar Smith | buy | $1K – $15K |
| 2002-06-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |